Cardiovascular steroid actions: swift swallows or sluggish snails?

Cardiovascular Research

Volumn 40, Issue 1, 1998, Pages 34-44

  Christ, Michael ^a   Wehling, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Hormones; Receptors; Vasoconstriction dilation

Indexed keywords

ALDOSTERONE; ANDROGEN; ESTRADIOL; GLUCOCORTICOID; HYDROCORTISONE; MINERALOCORTICOID; PROGESTERONE; TESTOSTERONE;

BLOOD CLOTTING; BLOOD VOLUME; CARDIOVASCULAR DISEASE; CORTICOSTEROID THERAPY; DRUG DNA INTERACTION; DRUG EFFECT; DRUG MECHANISM; ELECTROLYTE BALANCE; LIPID BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADRENAL CORTEX HORMONES; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; ENDOTHELIUM, VASCULAR; FEMALE; GONADAL STEROID HORMONES; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, STEROID;

EID: 0032190474     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00147-3     Document Type: Review

References (105)

1. [1] Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-895.
2. [2] Kornel L. The role of vascular steroid receptors in the control of vascular contractility and peripheral vascular resistance. J Steroid Biochem Mol Biol 1993;45:195-203.
3. [3] Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994;89:1943-1950.
4. [4] Kornel L, Nelson WA, Manisundaram B, Chigurupati R, Hayashi T. Mechanism of the effects of glucocorticoids and mineralocorticoids on vascular smooth muscle contractility. Steroids 1993;58:580-587.
5. [5] Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen receptor in cultured endothelial cells. Circulation 1996;94:727-733.
6. [6] McInerney EM, Tsai MJ, O'Malley BW, Katzenellenbogen BS. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Natl Acad Sci USA 1996;93:10069-10073.
7. [7] Smith CL, Oñate SA, Tsai MJ, O'Malley BW CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 1996;93:8884-8888.
8. [8] Wehling M. Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s. J Mol Med 1995;73:439-447.
9. [9] Guetta V, Cannon III RO. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996;93:1928-1937.
10. [10] Rossier BC. Mechanisms of action of mineralocorticoid hormones. Endocr Res 1989;15:206-226.
11. [11] Langford HG, Snavely JR. Effect of DOCA on development of renoprival hypertension. Am J Physiol 1959;196:449-450.
12. [12] Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994;93:2578-2583.
13. [13] Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809-820.
14. [14] Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994;28:1863-1867.
15. [15] Wehling M. Nongenomic actions of steroid hormones. Trends Endocrinol Metab 1994;5:347-353.
16. [16] Klein K, Henk W. Klinisch-experimentelle Untersuchungen über den Einfluss von Aldosteron auf Haemodynamik und Gerinnung. Z Kreisl Forsch 1964;52:40-53.
17. + efflux from arterial smooth muscle. Hypertension 1984;6:425-430.
18. [18] Wang W, McChain J, Zucker I. Aldosterone reduces baroreceptor discharge in the dog. Hypertension 1992;19:270-277.
19. [19] Moreau D, Chardigny JM, Rochette L. Effects of aldosterone and spironolactone on the isolated perfused rat heart. Pharmacology 1996;53:28-36.
20. [20] Zange J, Müller K, Gerzer R, Sippel K, Wehling M. Nongenomic effects of aldosterone on phosphocreatine levels in human calf muscle during recovery from exercise. J Clin Endocrinol Metab 1996;81:4296-4300.
21. 2+ and stimulation of a plasma membrane proton conductance. Proc Natl Acad Sci USA 1996;93:10500-10504.
22. [22] Christ M, Eisen C, Aktas J, Theisen K, Wehling M. The inositol-1,4,5-trisphosphate system is involved in rapid nongenomic effects of aldosterone in human mononuclear leukocytes. J Clin Endocrinol Metab 1993;77:1452-1457.
23. [23] Wehling M, Käsmayr J, Theisen K. Evidence for rapid, nongenomic effects of mineralocorticoids in lymphocytes involving the sodium-proton exchanger of the cell membrane. Am J Physiol 1991;260:E719-E726.
24. [24] Wehling M, Christ M, Gerzer R. Aldosterone-specific membrane receptors and related rapid, non-genomic effects. Trends Pharmacol Sci 1993;14:1-4.
25. [25] Christ M, Sippel K, Eisen C, Wehling M. Non-classical receptors for aldosterone in plasma membranes from pig kidneys. Mol Cell Endocrinol 1994;99:R31-R34.
26. [26] Meyer C, Christ M, Wehling M. Characterization and solubilization of novel aldosterone binding proteins in porcine liver microsomes. Eur J Biochem 1995;229:736-740.
27. [27] Wehling M, Christ M, Theisen K. Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action. Am J Physiol 1992;263:E974-E979.
28. [28] Arriza LA, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;23:268-275.
29. [29] Al-Dujaili EAS, Edwards CRW The development and application of direct radioimmunoassay for plasma aldosterone using 131-I-labelled ligand - comparison of three methods. J Clin Endocrinol Metab 1978;46:105-113.
30. +-antiport. Hypertension 1995;25:117-123.
31. [31] Christ M, Meyer C, Sippel K, Wehling M. Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C α. Biochem Biophys Res Commun 1995;213:123-129.
32. [32] Wehling M, Bauer MM, Ulsenheimer A, et al. Nongenomic effects of aldosterone on intracellular pH in vascular smooth muscle cells. Biochem Biophys Res Commun 1996;223:181-186.
33. [33] Wehling M, Ulsenheimer A, Schneider M, Neylon CB, Christ M. Rapid effects of aldosterone on free intracellular calcium in vascular smooth muscle and endothelial cells: subcellular localization of calcium release by single cell imaging. Biochem Biophys Res Commun 1994;204:475-481.
34. [34] Wehling M, Neylon CB, Fullerton M, Bobik A, Funder JW. Nongenomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells. Circ Res 1995;76:973-979.
35. [35] Greene EL, Kren S, Hosteller TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996;98:1063-1068.
36. [36] Stampfer MJ, Colditz GA, Willett WC. Menopause and heart disease: a review. Ann NY Acad Sci 1989;592:193-203.
37. [37] Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking and cardiovascular morbidity in women over 50. N Engl J Med 1985;313:1038-1043.
38. [38] Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1321-1327.
39. [39] Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effect of estrogen. FASEB J 1996;10:615-624.
40. [40] Colburn P, Buonassisi V. Estrogen binding sites in endothelial cell cultures. Science 1978;201:817-819.
41. [41] Espinosa E, Oemar BS, Lüscher TF. 17 beta-Estradiol and smooth muscle cell proliferation in aortic cells of male and female rats. Biochem Biophys Res Commun 1996;221:8-14.
42. [42] Vargas R, Wroblewska B, Rego A, Hatch J, Ramwell PW. Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery. Br J Pharmacol 1993;109:612-617.
43. [43] Sullivan TR, Karas RH, Aronovitz M. Estrogen inhibils the response-to-injury in a mouse carotid artery model. J Clin Invest 1995;96:2482-2488.
44. [44] Hishikawa K, Nakaki T, Marumo T, et al. Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett 1995;360:291-293.
45. [45] Mikkola T, Turunen P, Avela K, et al. 17 beta-Estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J Clin Endocrinol Metab 1995;80:1832-1836.
46. [46] Arnal JF, Clamens S, Pechet C, et al. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc Natl Acad Sci USA 1996;93:4108-4113.
47. [47] Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53.
48. [48] Foegh ML, Ramwell PW. Cardiovascular effects of estrogen: implication of the discovery of the estrogen receptor subtype beta. Curr Opin Nephrol Hypertens 1998;7:83-89.
49. [49] Wilson JD, Foster DW Reference values. In: Wilson JD, Foster DW, editors. Williams textbook of endocrinology, eighth ed. Philadelphia, PA: Saunders, 1992:2-3.
50. [50] Levrant SG, Barnes RB. Pharmacology of estrogens. In: Lobo RA, editor. Treatment of postmenopausal woman: basic and clinical aspects. New York: Raven Press, 1994:57-68.
51. [51] Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Effects of estrogen therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol 1995;75:264-268.
52. [52] Rosano CM, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1994;342:133-136.
53. [53] Gilligan DM, Quyyumi AA, Cannon 3rd RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994;89:2545-2551.
54. [54] Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon 3rd RO. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994;90:786-791.
55. [55] Raddino R, Manca C, Poli E, Bolognesi R, Visioli O. Effects of 17β-estradiol on the isolated rabbit heart. Arch Int Pharmacodyn 1986;28:57-65.
56. 2α-mediated contraction in the porcine coronary artery. Adv Prost Thromb Leuk Res 1989;19:277-280.
57. 2 in porcine coronary artery. Circulation 1995;91:2619-2626.
58. 2+ currents in A7r5 vascular smooth muscle cell line. Am J Physiol 1994;266:C975-C980.
59. [59] Kitazawa T, Hamada E, Kitazawa K, Gaznabi AK. Non-genomic mechanism of 17 beta-oestradiol-induced inhibition of contraction in mammalian vascular smooth muscle. J Physiol 1997;499:497-511.
60. [60] Sudhir K, Chou TM, Mullen WL, et al. Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries. J Am Coll Cardiol 1995;26:807-814.
61. [61] Farhat MY, Abi-Younes S, Dingaan B, Vargas R, Ramwell PW. Estradiol increases cyclic adenosine monophosphate in rat pulmonary vascular smooth muscle cells by a nongenomic mechanism. J Pharmacol Exp Ther 1996;276:652-657.
62. [62] Clarke R, van den Berg HW, Murphy RF. Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17β-estradiol. J Natl Cancer Inst 1990;82:1702-1705.
63. [63] Reddy AG, Shivaji S, Gupta PD. Effect of estradiol on the membrane fluidity of the rat vagina endothelial cells. J Steroid Biochem 1989;33:1229-1233.
64. [64] Willmer EN. Steroids and cell surfaces. Biol Rev 1961;36:368-398.
65. [65] Shivaji S, Jagannadham MV. Steroid-induced perturbation of membranes and its relevance to sperm acrosome reaction. Biochem Biophys Acta 1992;1108:99-109.
66. [66] Collins P, Shay J, Jiang C, Moss J. Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation 1994;90:1964-1968.
67. [67] Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in post-menopausal women. Ann Intern Med 1994;121:936-941.
68. [68] Song J, Standley PR, Zhang F, et al. Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J Pharmacol Exp Pharm 1996;277:1444-1453.
69. [69] Rutquist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993;85:1398-1406.
70. [70] Pietras R, Szego CM. Endometrial cell calcium and oestrogen action. Nature 1975;253:357-359.
71. [71] Pietras R, Szego CM. Metabolic and proliferative responses to estrogen by hepatocytes selected for plasma membrane binding sites for estradiol-17β. J Cell Physiol 1979;98:145-160.
72. [72] Pappas TC, Cametchu B, Watson CS. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J 1995;9:404-410.
73. [73] Perrot-Applanat M, Picard-Groyer MT, Lorenzo GF, Milgrom E. Immunocytochemical demonstration of estrogen and progesterone receptors in muscle cells of uterine arteries in rabbits and humans. Endocrinology 1988;123:1511-1519.
74. [74] Ford SP, Reynold LP, Farley DB, Bhatnagar RK, Van Orden DE. Interaction of ovarian steroids and periarterial alpha-1-adrenergic receptors in altering uterine blood flow during the estrous cycle of gilts. Am J Obstet Gynecol 1984;150:480-484.
75. 2+ currents in myometrial cells from immature and nonpregnant adult rats. Am J Physiol 1992;262:C293-C301.
76. [76] Bielefeldt K, Waite L, Abboud FM, Conklin JL. Nongenomic effects of progesterone on human intestinal smooth muscle cells. Am J Physiol 1996;271:G370-G376.
77. [77] Jiang CW, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur J Pharmacol 1992;211:163-167.
78. 2+ in single rat hepatocytes. Biochem J 1991;280:273-276.
79. [79] Morishita S. Prompt effects of progesterone on the adrenergic response of smooth muscles. Jpn J Pharmacol 1986;42:289-296.
80. [80] Blackmore PF, Neulen J, Lattanzio F, Beebe SJ. Cell surface-binding sites for progesterone mediate calcium uptake in human sperm. J Biol Chem 1991;266:18655-18659.
81. [81] Falkenstein E, Meyer C, Eisen C, Scriba PC, Wehling M. Full-length cDNA sequence of a progesterone membrane binding protein from porcine vascular smooth muscle cells. Biochem Biophys Res Commun 1996;229:86-89.
82. [82] Meyer C, Schmid R, Scriba PC, Wehling M. Purification and partial sequencing of high affinity progesterone-binding site(s) from porcine liver membranes. Eur J Biochem 1996;239:726-731.
83. [83] Webb OL, Lakarzewski PM, Glueck CJ. Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic androgenic steroids. Metabolism 1984;33:971-978.
84. [84] Ferrer M, Encabo A, Marín J, Balfagón G. Chronic treatment with anabolic steroid, nandrolone, inhibits vasodilator responses in rabbit aorta. Eur J Pharmacol 1994;252:233-241.
85. [85] Farhat MY, Wolfe R, Vargas R, Foegh ML, Ramwell PW. Effect of testosterone treatment on vasoconstrictor response of left anterior descending coronary artery in male and female pigs. J Cardiovasc Pharmacol 1995;25:495-500.
86. [86] Costarella CE, Stallone JN, Rutecki GW, Whittier FC. Testosterone causes direct relaxation of rat thoracic aorta. J Pharmacol Exp Ther 1996;277:34-39.
87. [87] Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation 1995;91:1154-1160.
88. [88] Lieberherr M, Grosse B, Kachkache M, Balsan S. Cell signaling and estrogens in female rat osteoblasts: a possible involvement of unconventional nonnuclear receptors. J Bone Min Res 8;11:1365-1376.
89. [89] Ross EJ, Linch DC. Gushing's syndrome - killing disease. Discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982;II:646-649.
90. [90] Page IH, McCubbin JW. Cardiovascular reactivity. Circ Res 1954;2:395-408.
91. [91] Whitworth JA, Brown MA, Kelly JJ, Williamson PM. Mechanisms of cortisol-induced hypertension in humans. Steroids 1995;60:76-80.
92. [92] Walker BR, Best R, Shackleton CH, Padfield PL, Edwards CRW. Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. Hypertension 1996;27:190-196.
93. [93] Sato A, Suzuki H, Murakami M, et al. Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 1994;23:25-30.
94. [94] Uno S, Guo DF, Nakajima M, et al. Glucocorticoid induction of rat angiotensin II type 1A receptor gene promoter. Biochem Biophys Res Commun 1994;204:210-215.
95. [95] Fishel RS, Eisenberg S, Shai SY, et al. Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle. Hypertension 1995;25:343-349.
96. [96] Axelrod L. Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of this mechanism contribute to pathogenesis of Cushing's syndrome and Addison's disease. Lancet 1983;I:904-906.
97. [97] Lewis GD, Campbell WB, Johnson AR. Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocrinology 1986;119:62-69.
98. [98] Connell JMC, Whitworth JA, Davies DL, et al. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 1987;5:425-433.
99. [99] Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Molinoff PB, Ruddon RW, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, ninth ed. 1996:1459-1486.
100. [100] Moyer ML, Borror KC, Bona BJ, DeFranco DB, Nordeen SK. Modulation of cell signaling pathways can enhance or impair glucocorticoid-induced gene expression without altering the state of receptor phosphorylation. J Biol Chem 1993;268:22933-22940.
101. [101] Walker BR, Phillips DIW, Noon JP, et al. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998;31:891-895.
102. [102] Pitt B. 'Escape' of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995;9:145-149.
103. [103] Pitt B. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J 1996;16(Suppl N): 107-110.
104. [104] Voisard R, Seitzer U, Baur R, et al. Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro. Int J Cardiol 1994;43:257-257.
105. [105] Volterrani M, Rosano G, Coats A, Beale C, Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med 1995;99:119-122.